HK1205450A1 - Medicine comprising combination of general anesthetic drug and hydrogen - Google Patents
Medicine comprising combination of general anesthetic drug and hydrogen Download PDFInfo
- Publication number
- HK1205450A1 HK1205450A1 HK15103729.5A HK15103729A HK1205450A1 HK 1205450 A1 HK1205450 A1 HK 1205450A1 HK 15103729 A HK15103729 A HK 15103729A HK 1205450 A1 HK1205450 A1 HK 1205450A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- anesthetic
- hydrogen
- medicine
- general
- hydrogen gas
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012-125535 | 2012-05-31 | ||
| JP2012125535 | 2012-05-31 | ||
| PCT/JP2013/065094 WO2013180240A1 (ja) | 2012-05-31 | 2013-05-30 | 全身麻酔薬と、水素とを組み合わせてなる、医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1205450A1 true HK1205450A1 (en) | 2015-12-18 |
Family
ID=49673427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15103729.5A HK1205450A1 (en) | 2012-05-31 | 2013-05-30 | Medicine comprising combination of general anesthetic drug and hydrogen |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150079197A1 (https=) |
| EP (1) | EP2857026A4 (https=) |
| JP (1) | JP6168420B2 (https=) |
| KR (1) | KR20150018832A (https=) |
| CN (1) | CN104394873A (https=) |
| AU (1) | AU2013268366A1 (https=) |
| BR (1) | BR112014029260A2 (https=) |
| CA (1) | CA2874579A1 (https=) |
| HK (1) | HK1205450A1 (https=) |
| IL (1) | IL235718A0 (https=) |
| IN (1) | IN2014MN02090A (https=) |
| MX (1) | MX2014014543A (https=) |
| NZ (1) | NZ701553A (https=) |
| RU (1) | RU2014152690A (https=) |
| SG (1) | SG11201407489TA (https=) |
| WO (1) | WO2013180240A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6253029B2 (ja) * | 2015-01-21 | 2017-12-27 | 大陽日酸株式会社 | 麻酔器用取付キット |
| US20180338995A1 (en) * | 2017-05-23 | 2018-11-29 | Perricone Hydrogen Water Company, Llc | Systems and methods for treatments using hydrogen and/or noble gases |
| US11129848B2 (en) * | 2017-08-08 | 2021-09-28 | Perricone Hydrogen Water Company, Llc | Medication enhancement using hydrogen |
| EP3814502A4 (en) * | 2018-06-29 | 2022-10-05 | John Mansell | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANESTHESIA-RELATED NEUROTOXICITY |
| US11123365B2 (en) | 2019-11-18 | 2021-09-21 | Perricone Hydrogen Water Company, Llc | Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof |
| JP7019910B2 (ja) * | 2020-07-21 | 2022-02-16 | ＭｉＺ株式会社 | 薬の副作用、薬の副作用に関連する症状、および／または、治療に伴う副作用を予防および／または改善するための組成物 |
| CN117861037A (zh) * | 2022-10-11 | 2024-04-12 | 上海氢医医疗科技有限公司 | 氢气吸入治疗自闭症 |
| CN119303200A (zh) * | 2024-12-17 | 2025-01-14 | 山东百多安医疗器械股份有限公司 | 一种可以释放氢气减少神经损伤的麻醉机 |
-
2013
- 2013-05-30 HK HK15103729.5A patent/HK1205450A1/en unknown
- 2013-05-30 BR BR112014029260A patent/BR112014029260A2/pt not_active Application Discontinuation
- 2013-05-30 CN CN201380028933.5A patent/CN104394873A/zh active Pending
- 2013-05-30 CA CA2874579A patent/CA2874579A1/en not_active Abandoned
- 2013-05-30 RU RU2014152690A patent/RU2014152690A/ru unknown
- 2013-05-30 NZ NZ701553A patent/NZ701553A/en not_active IP Right Cessation
- 2013-05-30 JP JP2014518736A patent/JP6168420B2/ja not_active Expired - Fee Related
- 2013-05-30 WO PCT/JP2013/065094 patent/WO2013180240A1/ja not_active Ceased
- 2013-05-30 EP EP13796554.7A patent/EP2857026A4/en not_active Withdrawn
- 2013-05-30 US US14/397,229 patent/US20150079197A1/en not_active Abandoned
- 2013-05-30 KR KR20147035945A patent/KR20150018832A/ko not_active Withdrawn
- 2013-05-30 MX MX2014014543A patent/MX2014014543A/es unknown
- 2013-05-30 IN IN2090MUN2014 patent/IN2014MN02090A/en unknown
- 2013-05-30 SG SG11201407489TA patent/SG11201407489TA/en unknown
- 2013-05-30 AU AU2013268366A patent/AU2013268366A1/en not_active Abandoned
-
2014
- 2014-11-16 IL IL235718A patent/IL235718A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104394873A (zh) | 2015-03-04 |
| CA2874579A1 (en) | 2013-12-05 |
| MX2014014543A (es) | 2015-06-05 |
| WO2013180240A1 (ja) | 2013-12-05 |
| BR112014029260A2 (pt) | 2017-06-27 |
| SG11201407489TA (en) | 2014-12-30 |
| KR20150018832A (ko) | 2015-02-24 |
| NZ701553A (en) | 2016-06-24 |
| IN2014MN02090A (https=) | 2015-09-04 |
| IL235718A0 (en) | 2015-01-29 |
| JPWO2013180240A1 (ja) | 2016-01-21 |
| EP2857026A4 (en) | 2015-11-04 |
| AU2013268366A1 (en) | 2015-03-19 |
| US20150079197A1 (en) | 2015-03-19 |
| JP6168420B2 (ja) | 2017-07-26 |
| EP2857026A1 (en) | 2015-04-08 |
| RU2014152690A (ru) | 2016-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2857026A1 (en) | Medicine comprising combination of general anesthetic drug and hydrogen | |
| Ma et al. | Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain | |
| Yang et al. | Fluoride activates microglia, secretes inflammatory factors and influences synaptic neuron plasticity in the hippocampus of rats | |
| Guimarães et al. | Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial | |
| Young et al. | Ethanol causes and lithium prevents neuroapoptosis and suppression of pERK in the infant mouse brain | |
| Sun et al. | Gastrodin relieved complete Freund's adjuvant-induced spontaneous pain by inhibiting inflammatory response | |
| Shan et al. | Dexmedetomidine ameliorates the neurotoxicity of sevoflurane on the immature brain through the BMP/SMAD signaling pathway | |
| Samantaray et al. | Chronic intermittent ethanol induced axon and myelin degeneration is attenuated by calpain inhibition | |
| D’andrea et al. | Hydroxytyrosol stimulates neurogenesis in aged dentate gyrus by enhancing stem and progenitor cell proliferation and neuron survival | |
| Wang et al. | CIH-induced neurocognitive impairments are associated with hippocampal Ca2+ overload, apoptosis, and dephosphorylation of ERK1/2 and CREB that are mediated by overactivation of NMDARs | |
| Zhu et al. | Withanolide-A treatment exerts a neuroprotective effect via inhibiting neuroinflammation in the hippocampus after pilocarpine-induced status epilepticus | |
| Flores et al. | Neonatal olfactory bulbectomy enhances locomotor activity, exploratory behavior and binding of NMDA receptors in pre-pubertal rats | |
| Moretti et al. | A single coadministration of subeffective doses of ascorbic acid and ketamine reverses the depressive-like behavior induced by chronic unpredictable stress in mice | |
| Haelewyn et al. | Neuroprotection by nitrous oxide: facts and evidence | |
| Figueiredo et al. | Alpha-linolenic acid treatment reduces the contusion and prevents the development of anxiety-like behavior induced by a mild traumatic brain injury in rats | |
| Harding et al. | Prenatal exposure to valproic acid and treatment with intranasal oxytocin have sex-specific effects on behavior in Long Evans rats | |
| Tourrel et al. | The antiapoptotic effect of remifentanil on the immature mouse brain: an ex vivo study | |
| Zare et al. | Anxiolytic activity of paraoxon is associated with alterations in rat brain glutamatergic system | |
| Zoladz et al. | Ketamine sex-and dose-dependently mitigates behavioral sequelae induced by a predator-based psychosocial stress model of post-traumatic stress disorder | |
| Zhao et al. | Morphine pretreatment protects against cerebral ischemic injury via a cPKCγ-mediated anti-apoptosis pathway | |
| Lee et al. | Inhibition of hexokinase leads to neuroprotection against excitotoxicity in organotypic hippocampal slice culture | |
| Mooney et al. | Prenatal exposure to ethanol affects postnatal neurogenesis in thalamus | |
| Nahas et al. | Anti-ceramidase LCL385 acutely reduces BCL-2 expression in the hippocampus but is not associated with an increase of learned helplessness in rats | |
| Guo et al. | Effect of Parecoxib on Hippocampus and Hypothalamic Orexin Neurons in Rats with Cerebral Infarction | |
| Sivandzade | Traumatic Brain Injury: Assessing the Pathogenic Impact of Chronic Smoking and Potential Countermeasures |